Ardelyx, Inc. (ARDX) Stock Analysis — Probabli.AI
AI-powered analysis for ARDX (Ardelyx, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. AI consensus: Bullish.
Last price: $5.97 · Market cap: $1.5B · AI consensus: Bullish
Ardelyx, Inc. is a promising biopharmaceutical company focusing on addressing unmet medical needs, especially in the kidney and gastrointestinal medicine sectors. Recent FDA fast track designations, successful clinical outcomes, and strong analyst support bolster the outlook. Despite some challenges related to cash burn and patents, Ardelyx's innovative pipeline and strategic partnerships make…
Probabilistic 1-Year Outlook
- Bull 6000% · Neutral 2500% · Bear 1500%
- Ardelyx is well-positioned with its recent FDA fast track designation and expanded pipeline. Analyst consensus is overwhelmingly positive, suggesting potential strong performance ahead.
5-Year Outlook
- Bull 5500% · Neutral 3000% · Bear 1500%
SWOT Highlights
- Strength: FDA fast track designation for a kidney drug
- Strength: Expanded pipeline with new drug acquisition
- Risk: High cash burn rate
- Risk: Uncertainty around patent challenges
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
7 Wall Street analysts rate ARDX a STRONG BUY with a mean price target of $15.14.
Analysis generated Apr 29, 2026 · Model: gpt-4o. Run a fresh analysis on probabli.xyz/stock/ARDX.
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.